Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Saved in:
| Title: | Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. |
|---|---|
| Authors: | Chia DKA; Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore., Sundar R; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; The N.1 Institute for Health, National University of Singapore, Singapore, Singapore., Kim G; Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore., Ang JJ; Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore., Lum JHY; Department of Pathology, National University Hospital, National University Health System, Singapore, Singapore., Nga ME; Department of Pathology, National University Hospital, National University Health System, Singapore, Singapore., Goh GH; Department of Pathology, National University Hospital, National University Health System, Singapore, Singapore., Seet JE; Department of Pathology, National University Hospital, National University Health System, Singapore, Singapore., Chee CE; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore., Tan HL; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore., Ho J; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore., Ngoi NYL; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore., Lee MXW; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore., Muthu V; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore., Chan GHJ; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore., Pang ASL; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore., Ang YLE; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore., Choo JRE; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore., Lim JSJ; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore., Teh JL; Department of General Surgery, Ng Teng Fong General Hospital, Singapore, Singapore., Lwin A; Department of General Surgery, Ng Teng Fong General Hospital, Singapore, Singapore., Soon Y; Department of General Surgery, Ng Teng Fong General Hospital, Singapore, Singapore., Shabbir A; Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Division of Surgical Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore., So JBY; Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore. jimmyso@nus.edu.sg.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. jimmyso@nus.edu.sg.; Division of Surgical Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore. jimmyso@nus.edu.sg., Yong WP; Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. |
| Source: | Annals of surgical oncology [Ann Surg Oncol] 2022 Dec; Vol. 29 (13), pp. 8597-8605. Date of Electronic Publication: 2022 Sep 07. |
| Publication Type: | Clinical Trial, Phase II; Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
